rhBNP联合DA与多巴酚丁胺治疗重症心衰疗效及安全性分析

Efficacy and the safety analysis of rhBNP combined with dopamine and dobutamine in treating severe heart failure

目的:探讨重组人脑钠肽(rhBNP)加用多巴胺(DA)与多巴酚丁胺治疗重症心衰患者疗效及安全性。方法:抽选某医院治疗的66例重症心衰患者(符合心功能NYHAⅢ-Ⅳ级、心脏超声提示LVEF<40%)。随机分为W组和Z组,Z组予常规标准化抗心衰治疗,W组在Z组治疗的基础上予rhBNP加用DA和多巴酚丁胺治疗;评估两组患者治疗后的心功能分级、氨基末端脑钠肽前体(NT-proBNP)水平、LVEF及药物不良反应等指标。结果:治疗后W组比Z组患者心功能分级明显改善,且W组患者NT-proBNP及LVEF的改善程度优于Z组,差异有统计学意义(P<0.05),而药物对两组患者产生的不良反应差异无统计学意义(P>0.05)。结论:rhBNP联合DA与多巴酚丁胺治疗重症心衰患者安全有效,值得推广。

Objective:To explore the efficacy and safety of recombinant human brain sodium peptide(rhBNP)combined with dopamine(DA)and dobutamine in patients with severe heart failure.Methods:66 patients with severe heart failure(meet NYHA classⅢ-Ⅳcardiac function,and echocardiography suggests LVEF<40%)were selected in the Hospital and randomly divided into groups W and Z.Group Z was given routine standardized anti-HF therapy while Group W with rhBNP plus DA and dobutamine.After treatment,the cardiac function grading,N-terminal pro-brain natriuretic peptide(NT-proBNP)level,LVEF and adverse drug reactions were evaluated in the two groups.Results:After treatment,cardiac function grade,NT-proBNP and LVEF in Group W improved better than that in Group Z(P<0.05).There was no significant difference in adverse effects between the two groups(P>0.05).Conclusion:The combination of rhBNP with DA and dobutamine is safe and effective in treating patients with severe heart failure and deserves promotion.